An Open-Label, Randomized, Crossover Study Assessing the Effect of Para-amino salicylic acid (PAS) on the Pharmacokinetics of Tenofovir Disproxil Fumarate in Korean Healthy Subjects

Trial Profile

An Open-Label, Randomized, Crossover Study Assessing the Effect of Para-amino salicylic acid (PAS) on the Pharmacokinetics of Tenofovir Disproxil Fumarate in Korean Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Aminosalicylic acid (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B; HIV infections; Tuberculosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 Jul 2017 New trial record
    • 27 Jun 2017 Results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top